Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases.
Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV).
The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).
The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases.
It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 31, 24 | -1.56 Decreased by -27.87% | -1.05 Decreased by -48.57% |
| Aug 1, 24 | -1.02 Increased by +29.66% | -0.90 Decreased by -13.33% |
| May 2, 24 | -0.48 Increased by +54.72% | -1.05 Increased by +54.29% |
| Feb 22, 24 | -0.86 Decreased by -13.16% | -1.01 Increased by +14.85% |
| Nov 2, 23 | -1.22 Decreased by -193.85% | -1.21 Decreased by -0.83% |
| Aug 3, 23 | -1.45 Decreased by -150.00% | -1.20 Decreased by -20.83% |
| May 4, 23 | -1.06 Decreased by -127.53% | -0.87 Decreased by -21.84% |
| Feb 23, 23 | -0.76 Decreased by -119.39% | -0.39 Decreased by -94.87% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 2.38 M Increased by +158.08% | -213.72 M Decreased by -30.78% | Decreased by -8.98 K% Decreased by -325.19% |
| Jun 30, 24 | 3.08 M Increased by +124.17% | -138.38 M Increased by +28.95% | Decreased by -4.50 K% Decreased by -393.93% |
| Mar 31, 24 | 56.38 M Increased by +20.69% | -65.28 M Increased by +53.69% | Decreased by -115.79% Increased by +61.63% |
| Dec 31, 23 | 16.79 M Decreased by -22.96% | -115.97 M Decreased by -14.14% | Decreased by -690.85% Decreased by -48.15% |
| Sep 30, 23 | -4.10 M Decreased by -101.10% | -163.41 M Decreased by -193.21% | Increased by +3.99 K% Increased by +8.35 K% |
| Jun 30, 23 | -12.72 M Increased by +70.20% | -194.78 M Decreased by -154.63% | Increased by +1.53 K% Increased by +754.38% |
| Mar 31, 23 | 46.71 M Decreased by -96.20% | -140.96 M Decreased by -127.18% | Decreased by -301.76% Decreased by -815.63% |
| Dec 31, 22 | 21.79 M Decreased by -97.31% | -101.60 M Decreased by -119.34% | Decreased by -466.30% Decreased by -818.88% |